Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV000415891 | SCV000493565 | uncertain significance | not provided | 2016-07-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001242512 | SCV001415605 | likely benign | Retinitis pigmentosa 12; Leber congenital amaurosis 8 | 2024-12-28 | criteria provided, single submitter | clinical testing | |
Knight Diagnostic Laboratories, |
RCV001270085 | SCV001448893 | uncertain significance | Pigmented paravenous retinochoroidal atrophy | 2019-02-22 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001563884 | SCV001786931 | uncertain significance | Leber congenital amaurosis 8 | 2021-07-14 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001563885 | SCV001786932 | uncertain significance | Retinitis pigmentosa 12 | 2021-07-14 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002521478 | SCV003543404 | uncertain significance | Inborn genetic diseases | 2021-10-05 | criteria provided, single submitter | clinical testing | The c.2746C>T (p.L916F) alteration is located in exon 8 (coding exon 8) of the CRB1 gene. This alteration results from a C to T substitution at nucleotide position 2746, causing the leucine (L) at amino acid position 916 to be replaced by a phenylalanine (F). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV001828390 | SCV002090184 | uncertain significance | Leber congenital amaurosis | 2019-11-11 | no assertion criteria provided | clinical testing |